MENU
+Compare
BIIB
Stock ticker: NASDAQ
AS OF
Sep 11, 04:59 PM (EDT)
Price
$148.89
Change
+$6.28 (+4.40%)
Capitalization
20.91B

BIIB Biogen Forecast, Technical & Fundamental Analysis

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan... Show more

Industry: #Biotechnology
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BIIB with price predictions
Sep 10, 2025

BIIB in upward trend: 10-day moving average crossed above 50-day moving average on August 13, 2025

The 10-day moving average for BIIB crossed bullishly above the 50-day moving average on August 13, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 02, 2025. You may want to consider a long position or call options on BIIB as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BIIB just turned positive on September 03, 2025. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in of 57 cases over the following month. The odds of a continued upward trend are .

BIIB moved above its 50-day moving average on August 13, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 152 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BIIB broke above its upper Bollinger Band on August 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIIB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.237) is normal, around the industry mean (9.546). P/E Ratio (14.243) is within average values for comparable stocks, (23.839). BIIB's Projected Growth (PEG Ratio) (4.705) is slightly higher than the industry average of (1.753). BIIB's Dividend Yield (0.000) is considerably lower than the industry average of (0.028). P/S Ratio (2.178) is also within normal values, averaging (3.446).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

View a ticker or compare two or three
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BIIB is expected to report earnings to fall 29.80% to $3.84 per share on October 22

Biogen BIIB Stock Earnings Reports
Q3'25
Est.
$3.84
Q2'25
Beat
by $1.48
Q1'25
Beat
by $0.06
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.31
The last earnings report on July 31 showed earnings per share of $5.47, beating the estimate of $3.99. With 1.71M shares outstanding, the current market capitalization sits at 20.91B.
A.I. Advisor
published General Information

General Information

a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Binney Street
Phone
+1 617 679-2000
Employees
7570
Web
https://www.biogen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QQQS32.080.72
+2.28%
Invesco NASDAQ Future Gen 200 ETF
SPXX18.350.09
+0.49%
Nuveen S&P 500 Dynamic Overwrite Fund
ETV14.230.04
+0.31%
Eaton Vance Tax-Managed Buy-Write Opportunities Fund
GCV4.140.01
+0.24%
Gabelli Convertible and Income Securities Fund (The)
CCZ60.85N/A
N/A
Comcast Holdings Corp

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+4.37%
PFE - BIIB
56%
Loosely correlated
+1.18%
MRK - BIIB
49%
Loosely correlated
+1.33%
AMGN - BIIB
48%
Loosely correlated
+1.52%
NVS - BIIB
45%
Loosely correlated
+0.91%
GSK - BIIB
44%
Loosely correlated
+2.42%
More